Antibody engineering and its therapeutic applications

References

• Kaunitz JD. Development of monoclonal antibodies: the dawn of mAb rule. Dig Dis Sci. 2017;62(4):831–832. doi:10.1007/s10620-017-4478-1.
   PubMed Web of Science ®Google Scholar
• Gavilondo JV, Larrick JW. Antibody engineering at the millennium. Biotechniques. 2000;29(1):128–145. doi:10.2144/00291ov01.
   PubMed Web of Science ®Google Scholar
• Saeed AFUH, Wang R, Ling S, et al. Antibody engineering for pursuing a healthier future. Front Microbiol. 2017;8:495. doi:10.3389/fmicb.2017.00495.
   PubMed Web of Science ®Google Scholar
• Parray HA, Shukla S, Samal S, et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol. 2020; 85:106639. doi:10.1016/j.intimp.2020.106639.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9(10):767–774. doi:10.1038/nrd3229.
   PubMed Web of Science ®Google Scholar
• Chiu ML, Goulet DR, Teplyakov A, et al. Antibody structure and function: the basis for engineering therapeutics. Antibodies. 2019;8(4):55. doi:10.3390/antib8040055.
   Web of Science ®Google Scholar
• Schroeder HW, Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41–S52. doi:10.1016/j.jaci.2009.09.046.
   PubMed Web of Science ®Google Scholar
• Feige MJ, Gräwert MA, Marcinowski M, et al. The structural analysis of shark IgNAR antibodies reveals evolutionary principles of immunoglobulins. Proc Natl Acad Sci U S A. 2014;111(22):8155–8160. doi:10.1073/pnas.1321502111.
   PubMed Web of Science ®Google Scholar
• Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007;77(1):13–22. doi:10.1007/s00253-007-1142-2.
   PubMed Web of Science ®Google Scholar
• Maynard J, Georgiou G. Antibody engineering. Annu Rev Biomed Eng. 2000;2(1):339–376. doi:10.1146/annurev.bioeng.2.1.339.
   PubMedGoogle Scholar
• Orlandi R, Güssow DH, Jones PT, et al. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86(10):3833–3837. doi:10.1073/pnas.86.10.3833.
   PubMed Web of Science ®Google Scholar
• Loo L, Robinson MK, Adams GP. Antibody engineering principles and applications. Cancer J. 2008;14(3):149–153. doi:10.1097/PPO.0b013e318173a5d5.
   PubMed Web of Science ®Google Scholar
• Huse WD, Sastry L, Iverson SA, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989;246(4935):1275–1281. doi:10.1126/science.2531466.
   PubMed Web of Science ®Google Scholar
• Ward ES, Güssow D, Griffiths AD, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341(6242):544–546. doi:10.1038/341544a0.
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol. 2005;23(9):1105–1116. doi:10.1038/nbt1126.
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220–233. doi:10.1111/j.1476-5381.2009.00190.x.
   PubMed Web of Science ®Google Scholar
• Kulshreshtha P, Bhatnagar R. Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis. Mol Immunol. 2011;48(15–16):1958–1965. doi:10.1016/j.molimm.2011.05.024.
   PubMed Web of Science ®Google Scholar
• Almagro JC, Fransson J. Humanization of antibodies. Front Biosci. 2008;13:1619–1633. doi:10.2741/2786.
   PubMed Web of Science ®Google Scholar
• Wu H, Nie Y, Huse WD, et al. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J Mol Biol. 1999;294(1):151–162. doi:10.1006/jmbi.1999.3141.
   PubMed Web of Science ®Google Scholar
• Lee E-C, Liang Q, Ali H, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol. 2014;32(4) :356–363. doi:10.1038/nbt.2825.
   PubMed Web of Science ®Google Scholar
• Lo K-M, Leger O, Hock B. Antibody engineering. Antibodies Infect Dis. 2015;319–343.
   Google Scholar
• Ma B, Osborn M. Transgenic animals for the generation of human antibodies. In: Rüker F, Wozniak-Knopp G., eds. Introduction to Antibody Engineering. Cham: Springer; 2021:97–127.
   Google Scholar
• Brewis N. Improvement of key characteristics of antibodies. In: Rüker F, Wozniak-Knopp G., eds. Introduction to Antibody Engineering. Cham: Springer; 2021:303–317.
   Google Scholar
• Zhou Q, Qiu H. The mechanistic impact of N-glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins. J Pharm Sci. 2019;108(4):1366–1377. doi:10.1016/j.xphs.2018.11.029.
   PubMed Web of Science ®Google Scholar
• Bessa J, Boeckle S, Beck H, et al. The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res. 2015;32(7):2344–2359. doi:10.1007/s11095-015-1627-0.
   PubMed Web of Science ®Google Scholar
• Jones TD, Crompton LJ, Carr FJ, et al. Deimmunization of monoclonal antibodies. In: Dimitrov A., ed. Therapeutic Antibodies. Humana Press; 2009:405–423.
   Google Scholar
• Cai HH. Therapeutic Monoclonal Antibodies Approved by FDA in 2020. 2021.
   Google Scholar
• Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11(1):19–20. doi:10.1038/nrd3629.
   PubMed Web of Science ®Google Scholar
• Khongorzul P, Ling CJ, Khan FU, et al. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19. doi:10.1158/1541-7786.MCR-19-0582.
   PubMed Web of Science ®Google Scholar
• Dickgiesser S, Rieker M, Rasche N. Antibody–drug conjugates. In: Rüker F, Wozniak-Knopp G, eds. Introduction to Antibody Engineering. Cham: Springer; 2021:189–214.
   Google Scholar
• Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–1135. doi:10.1056/NEJMoa2035807.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17(3):197–223. doi:10.1038/nrd.2017.227.
   PubMed Web of Science ®Google Scholar
• Ridwansyah H, Kartamihardja AHS, Bashari MH, et al. The potency of radiolabelled monoclonal antibody anti-CD20 as a targeted therapy for B-cell non-Hodgkin lymphoma: a review. Syst Rev Pharm. 2021;12(1):935–947.
   Google Scholar
• Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77(14):1603–1610. doi:10.1007/s40265-017-0802-5.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood J Am Soc Hematol. 2021;137(19):2634–2645. doi:10.1182/blood.2020007512.
   Google Scholar
• Nobre CF, Newman MJ, DeLisa A, et al. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations. Cancer Chemother Pharmacol. 2019;84(2):255–263. doi:10.1007/s00280-019-03875-6.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Keam SJ. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs. 2006;66(4):449–475. doi:10.2165/00003495-200666040-00005.
   PubMed Web of Science ®Google Scholar
• Lu R-M, Hwang Y-C, Liu I-J, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi:10.1186/s12929-019-0592-z.
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10(5):301–316. doi:10.1038/nri2761.
   PubMed Web of Science ®Google Scholar
• Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. MAbs. 2016;8(7):1177–1194. doi:10.1080/19420862.2016.1212149.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Wagstaff AJ. Alemtuzumab. Alemtuzumab. Drugs. 2003;63(12):1229–1243. doi:10.2165/00003495-200363120-00003.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499. doi:10.1056/NEJMoa1501031.
   PubMed Web of Science ®Google Scholar
• Neijssen J, Cardoso RMF, Chevalier KM, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021;296:100641. doi:10.1016/j.jbc.2021.100641.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948.
   PubMed Web of Science ®Google Scholar
• Kim ES. Avelumab: first global approval. Drugs. 2017;77(8):929–937. doi:10.1007/s40265-017-0749-6.
   PubMed Web of Science ®Google Scholar
• Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803–2835. doi:10.2165/00003495-200363240-00009.
   PubMed Web of Science ®Google Scholar
• Lamore R, Parmar S, Patel K, et al. Belimumab (benlysta): a breakthrough therapy for systemic lupus erythematosus. P T. 2012;37(4):212–226.
   PubMedGoogle Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096. e5. doi:10.1016/j.jaci.2013.05.020.
   PubMed Web of Science ®Google Scholar
• Barber EL, Zsiros E, Lurain JR, et al. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol. 2013;24(3):258–264. doi:10.3802/jgo.2013.24.3.258.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. Obstetrical Gynecol Surv. 2014;69(7):402–404. doi:10.1097/01.ogx.0000452705.82050.e4.
   Web of Science ®Google Scholar
• Johnson S, Gerding DN. Bezlotoxumab. Clin Infect Dis. 2019;68(4):699–704. doi:10.1093/cid/ciy577.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Stracke F, Stadlmayr G, et al. Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains. Biochem Biophys Rep. 2021;26:100959. doi:10.1016/j.bbrep.2021.100959.
   PubMedGoogle Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306. doi:10.1056/NEJMoa1315231.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–238. doi:10.1080/19420862.2018.1556465.
   PubMed Web of Science ®Google Scholar
• Ligi A. Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. 2020.
   Google Scholar
• Dhimolea E. Canakinumab. MAbs. 2010;2(1):3–13. doi:10.4161/mabs.2.1.10328.
   PubMed Web of Science ®Google Scholar
• Maher J, Adami AA. Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies?Cancer Res. 2013;73(18):5613–5617. doi:10.1158/0008-5472.CAN-13-1852.
   PubMed Web of Science ®Google Scholar
• Elliott W, Chan J. Casirivimab + Imdevimab injection. Internal Medicine Alert. 2020;42(24).
   Google Scholar
• Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137–147. doi:10.4161/mabs.2.2.11271.
   PubMed Web of Science ®Google Scholar
• Dantas-Barbosa C, de Macedo Brigido M, Maranhao AQ. Antibody phage display libraries: contributions to oncology. Int J Mol Sci. 2012;13(5):5420–5440. doi:10.3390/ijms13055420.
   PubMed Web of Science ®Google Scholar
• Mottershead M, Neuberger J. Daclizumab. Expert Opin Biol Ther. 2007;7(10):1583–1596. doi:10.1517/14712598.7.10.1583.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   Google Scholar
• Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63–82. doi:10.2165/11203300-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Dinutuximab: a review in high-risk neuroblastoma. Target Oncol. 2016;11(2):247–253. doi:10.1007/s11523-016-0420-2.
   PubMed Web of Science ®Google Scholar
• Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766–1772. doi:10.1001/jamaoncol.2020.4515.
   PubMed Web of Science ®Google Scholar
• D’Ippolito D, Pisano M. Dupilumab (dupixent): an interleukin-4 receptor antagonist for atopic dermatitis. Pharm Ther. 2018;43(9):532.
   Google Scholar
• Alsharedi M, Srivastava R, Elmsherghi N. Durvalumab for the treatment of urothelial carcinoma. Drugs Today (Barc)). 2017;53(12):647–652. doi:10.1358/dot.2017.53.12.2733054.
   PubMed Web of Science ®Google Scholar
• Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9(1):86–120. doi:10.1007/s13238-017-0457-8.
   PubMed Web of Science ®Google Scholar
• McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327–2345. doi:10.2165/11208300-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631. doi:10.1056/NEJMoa1505654.
   PubMed Web of Science ®Google Scholar
• Franchini M, Marano G, Pati I, et al. Emicizumab for the treatment of haemophilia A: a narrative review. Blood Transfus. 2019;17(3):223–228. doi:10.2450/2019.0026-19.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664.
   PubMed Web of Science ®Google Scholar
• Mazumdar S, Greenwald. Golimumab. In D. Golimumab. MAbs. 2009;1(5):422–431. doi:10.4161/mabs.1.5.9286.
   PubMed Web of Science ®Google Scholar
• Markham A. Guselkumab: first global approval. Drugs. 2017;77(13):1487–1492. doi:10.1007/s40265-017-0800-7.
   PubMed Web of Science ®Google Scholar
• Beccari MV, Mogle BT, Sidman EF, et al. Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection. Antimicrob Agents Chemother. 2019;63(6). doi:10.1128/AAC.00110-19.
   PubMed Web of Science ®Google Scholar
• Rizza SA, Bhatia R, Zeuli J, et al. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection. Drugs Today (Barc)). 2019; 55(1):25–34. doi:10.1358/dot.2019.55.1.2895651.
   PubMed Web of Science ®Google Scholar
• Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520. doi:10.1056/NEJMoa1502000.
   PubMed Web of Science ®Google Scholar
• De Goeij BE, Janmaat ML, Andringa G, et al. Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent anti-Tumor Activity in Preclinical Models of Hematological Malignancies. Washington, DC: American Society of Hematology; 2019.
   Google Scholar
• Melsheimer R, Geldhof A, Apaolaza I, et al. Remicade®(infliximab): 20 years of contributions to science and medicine. Biologics targets Ther. 2019;13:139.
   PubMed Web of Science ®Google Scholar
• Sondak VK, Smalley KSM, Kudchadkar R, et al. Ipilimumab. Nat Rev Drug Discov. 2011;10(6):411–412. doi:10.1038/nrd3463.
   PubMed Web of Science ®Google Scholar
• Krupashankar DS, Dogra S, Kura M, et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014;71(3):484–492. doi:10.1016/j.jaad.2014.01.897.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Zhu TH, et al. Ixekizumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb)). 2016;6(1):25–37. doi:10.1007/s13555-016-0102-0.
   PubMed Web of Science ®Google Scholar
• Syed YY. Lanadelumab: first global approval. Drugs. 2018;78(15):1633–1637. doi:10.1007/s40265-018-0987-2.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Moore DC, Elmes JB, Shibu PA, et al. Mogamulizumab: an anti-CC chemokine receptor 4 antibody for T-cell lymphomas. Ann Pharmacother. 2020;54(4):371–379. doi:10.1177/1060028019884863.
   PubMed Web of Science ®Google Scholar
• Baker DE. Natalizumab: overview of its pharmacology and safety. Rev Gastroenterol Disord. 2007;7(1):38–46.
   PubMed Web of Science ®Google Scholar
• Díaz-Serrano A, Sánchez-Torre A, Paz-Ares L. Necitumumab for the treatment of advanced non-small-cell lung cancer. Future Oncol. 2019;15(7):705–716. doi:10.2217/fon-2018-0594.
   PubMed Web of Science ®Google Scholar
• Sun L-M, Liu Y-C, Li W, et al. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression. Eur Rev Med Pharmacol Sci. 2017;21(6):1198–1205.
   PubMed Web of Science ®Google Scholar
• Greig SL. Obiltoxaximab: first global approval. Drugs. 2016;76(7):823–830. doi:10.1007/s40265-016-0577-0.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602–1604. doi:10.1038/leu.2015.14.
   PubMed Web of Science ®Google Scholar
• Shirley M. Olaratumab: first global approval. Drugs. 2017;77(1):107–112. doi:10.1007/s40265-016-0680-2.
   PubMed Web of Science ®Google Scholar
• Fenton C, Scott LJ, Plosker GL. Palivizumab. Pediatric Drugs. 2004;6(3):177–197. doi:10.2165/00148581-200406030-00004.
   PubMedGoogle Scholar
• Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J Immunother Cancer. 2015;3(1):1–13. doi:10.1186/s40425-015-0078-9.
   PubMedGoogle Scholar
• Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs. 2012;72(3):353–360. doi:10.2165/11209000-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Polatuzumab vedotin: first global approval. Drugs. 2019;79(13):1467–1475. doi:10.1007/s40265-019-01175-0.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Zatarain-Barrón ZL, Cardona AF, et al. Ramucirumab in the treatment of non-small cell lung cancer. Expert Opin Drug Saf. 2017;16(5):637–644. doi:10.1080/14740338.2017.1313226.
   PubMed Web of Science ®Google Scholar
• Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Ranibizumab. Drugs. 2007;67(8):1199–1206. doi:10.2165/00003495-200767080-00007.
   PubMed Web of Science ®Google Scholar
• Migone T-S, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361(2):135–144. doi:10.1056/NEJMoa0810603.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, Res-5-0010 Study Group, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. doi:10.1164/rccm.201103-0396OC.
   PubMed Web of Science ®Google Scholar
• Banaszczyk K. Risankizumab in the treatment of psoriasis - literature review. Reumatologia. 2019;57(3):158–162. doi:10.5114/reum.2019.86426.
   PubMedGoogle Scholar
• Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood J Am Soc Hematol. 1997;90(6):2188–2195. doi:10.1182/blood.V90.6.2188.2188_2188_2195.
   Google Scholar
• Du P, Geng J, Wang F, et al. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Int J Med Sci. 2021;18(6):1356–1362. doi:10.7150/ijms.53564.
   PubMed Web of Science ®Google Scholar
• Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5–21. doi:10.1177/2040622317738910.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol. 2010;28(23):3701–3708. doi:10.1200/JCO.2009.27.2377.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Deodhar A, Van der Heijde D, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021;80(Suppl 1):314.2–315. doi:10.1136/annrheumdis-2021-eular.2603.
   Google Scholar
• De Rossi N, Scarpazza C, Filippini C, et al. Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up. EClinicalMedicine. 2020;25:100459.
   PubMedGoogle Scholar
• Zhao M, Lu J, Tang Y, et al. Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. Eur J Clin Pharmacol. 2021;77(3):311–319. doi:10.1007/s00228-020-03017-5.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease. Gastroenterology. 2018;154(6):1660–1671. doi:10.1053/j.gastro.2018.01.043.
   PubMed Web of Science ®Google Scholar
• Singh H, Grewal N, Arora E, et al. Vedolizumab: a novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016;7(1):4–9. doi:10.4103/0976-9668.175016.
   PubMedGoogle Scholar
• Kumar R, Parray HA, Shrivastava T, et al. Phage display antibody libraries: a robust approach for generation of recombinant human monoclonal antibodies. Int J Biol Macromol. 2019;135:907–918. doi:10.1016/j.ijbiomac.2019.06.006.
   PubMed Web of Science ®Google Scholar
• Barbas CF, III, Burton DR. Selection and evolution of high-affinity human anti-viral antibodies. Trends Biotechnol. 1996;14(7):230–234. doi:10.1016/0167-7799(96)10029-9.
   PubMed Web of Science ®Google Scholar
• Persson M, Caothien RH, Burton DR. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci U S A. 1991;88(6):2432–2436. doi:10.1073/pnas.88.6.2432.
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR, de Bruïne AP, Hufton SE, et al. Antibody phage display technology and its applications. Immunotechnology. 1998;4(1) :1–20. doi:10.1016/S1380-2933(98)00007-4.
   PubMedGoogle Scholar
• Griffiths AD, Duncan AR. Strategies for selection of antibodies by phage display. Curr Opin Biotechnol. 1998;9(1):102–108. doi:10.1016/S0958-1669(98)80092-X.
   PubMed Web of Science ®Google Scholar
• Griffiths AD, Malmqvist M, Marks JD, et al. Human anti-self antibodies with high specificity from phage display libraries. Embo J. 1993;12(2):725–734. doi:10.1002/j.1460-2075.1993.tb05706.x.
   PubMed Web of Science ®Google Scholar
• Benhar I. Design of synthetic antibody libraries. Expert Opin Biol Ther. 2007;7(5):763–779. doi:10.1517/14712598.7.5.763.
   PubMed Web of Science ®Google Scholar
• Knappik A, Ge L, Honegger A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000;296(1):57–86. doi:10.1006/jmbi.1999.3444.
   PubMed Web of Science ®Google Scholar
• de Wildt RM, Mundy CR, Gorick BD, et al. Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat Biotechnol. 2000;18(9):989–994. doi:10.1038/79494.
   PubMed Web of Science ®Google Scholar
• Løset GÅ, Løbersli I, Kavlie A, et al. Construction, evaluation and refinement of a large human antibody phage library based on the IgD and IgM variable gene repertoire. J Immunol Methods. 2005;299(1–2):47–62. doi:10.1016/j.jim.2005.01.014.
   PubMed Web of Science ®Google Scholar
• Pini A, Viti F, Santucci A, et al. Design and use of a phage display library human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273(34):21769–21776. doi:10.1074/jbc.273.34.21769.
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR, Winter G. By-passing immunisation: human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol. 1992;227(2):381–388. doi:10.1016/0022-2836(92)90894-P.
   PubMed Web of Science ®Google Scholar
• Jirholt P, Ohlin M, Borrebaeck CA, et al. Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework. Gene. 1998;215(2):471–476. doi:10.1016/S0378-1119(98)00317-5.
   PubMed Web of Science ®Google Scholar
• Barbas CF, Hu D, Dunlop N, et al. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A. 1994;91(9):3809–3813. doi:10.1073/pnas.91.9.3809.
   PubMed Web of Science ®Google Scholar
• Wark KL, Hudson PJ. Latest technologies for the enhancement of antibody affinity. Adv Drug Deliv Rev. 2006;58(5–6) :657–670. doi:10.1016/j.addr.2006.01.025.
   PubMed Web of Science ®Google Scholar
• Harvey BR, Georgiou G, Hayhurst A, et al. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci U S A. 2004;101(25):9193–9198. doi:10.1073/pnas.0400187101.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350(1):126–144. doi:10.1016/j.jmb.2005.04.049.
   PubMed Web of Science ®Google Scholar
• Lamminmäki U, Paupério S, Westerlund-Karlsson A, et al. Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies. J Mol Biol. 1999;291(3):589–602. doi:10.1006/jmbi.1999.2981.
   PubMed Web of Science ®Google Scholar
• Gram H, Marconi LA, Barbas CF, et al. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci U S A. 1992;89(8):3576–3580. doi:10.1073/pnas.89.8.3576.
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity: mimicking affinity maturation. J Mol Biol. 1992;226(3):889–896. doi:10.1016/0022-2836(92)90639-2.
   PubMed Web of Science ®Google Scholar
• Wells JA. Additivity of mutational effects in proteins. Biochemistry. 1990;29(37):8509–8517. doi:10.1021/bi00489a001.
   PubMed Web of Science ®Google Scholar
• Yang XD, Corvalan JR, Wang P, et al. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol. 1999;66(3):401–410. doi:10.1002/jlb.66.3.401.
   PubMed Web of Science ®Google Scholar
• Ishida I, Tomizuka K, Yoshida H, et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells. 2002;4(1):91–102. doi:10.1089/153623002753632084.
   PubMedGoogle Scholar
• Brüggemann M, Osborn MJ, Ma B, et al. Strategies to obtain diverse and specific human monoclonal antibodies from transgenic animals. Transplantation. 2017;101(8):1770–1776. doi:10.1097/TP.0000000000001702.
   PubMed Web of Science ®Google Scholar
• Chen WC, Murawsky CM. Strategies for generating diverse antibody repertoires using transgenic animals expressing human antibodies. Front Immunol. 2018;9:460. doi:10.3389/fimmu.2018.00460.
   PubMed Web of Science ®Google Scholar
• Cameron B, Dabdoubi T, Berthou-Soulié L, et al. Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms. PLoS One. 2020;15(7):e0235815. doi:10.1371/journal.pone.0235815.
   PubMed Web of Science ®Google Scholar
• Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti–carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65(2):622–631.
   PubMed Web of Science ®Google Scholar
• Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol. 1997;15(7):637–640. doi:10.1038/nbt0797-637.
   PubMed Web of Science ®Google Scholar
• Yu X, Chan HTC, Fisher H, et al. Isotype switching converts anti-CD40 antagonism to agonism to elicit potent antitumor activity. Cancer Cell. 2020;37(6):850–866.e7. doi:10.1016/j.ccell.2020.04.013.
   PubMed Web of Science ®Google Scholar
• Wang L, Hoseini SS, Xu H, et al. Silencing Fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency. Cancer Immunol Res. 2019;7(12):2013–2024. doi:10.1158/2326-6066.CIR-19-0121.
   PubMed Web of Science ®Google Scholar
• Chao DT, Ma X, Li O, et al. Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies. Immunol Invest. 2009;38(1):76–92. doi:10.1080/08820130802608238.
   PubMed Web of Science ®Google Scholar
• Sorkin LS, Otto M, Baldwin WM, et al. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia . PAIN. 2010;149(1):135–142. doi:10.1016/j.pain.2010.01.024.
   PubMed Web of Science ®Google Scholar
• Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol. 2001;166(4):2571–2575. doi:10.4049/jimmunol.166.4.2571.
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9) :6591–6604. doi:10.1074/jbc.M009483200.
   PubMed Web of Science ®Google Scholar
• Buchanan A, Revell JD. Novel therapeutic proteins and peptides. In: Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Academic Press; 2015:171-197.
   Google Scholar
• Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol. 2002;20(3):264–269. doi:10.1038/nbt0302-264.
   PubMed Web of Science ®Google Scholar
• Penichet ML, Morrison SL. Antibody–cytokine fusion proteins for the therapy of cancer. J Immunol Methods. 2001;248(1–2):91–101. doi:10.1016/S0022-1759(00)00345-8.
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15(6):542–546. doi:10.1038/nbt0697-542.
   PubMed Web of Science ®Google Scholar
• Assa-Munt N, Jia X, Laakkonen P, et al. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry. 2001;40(8):2373–2378. doi:10.1021/bi002101f.
   PubMed Web of Science ®Google Scholar
• Li J, Ji J, Holmes LM, et al. Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Cancer Gene Ther. 2004;11(5):363–370. doi:10.1038/sj.cgt.7700707.
   PubMed Web of Science ®Google Scholar
• Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?MAbs. 2010;2(3):212–220. doi:10.4161/mabs.2.3.11780.
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Vasiljeva O, Richardson JH, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med. 2013;5(207):207ra144. doi:10.1126/scitranslmed.3006682.
   PubMed Web of Science ®Google Scholar
• Erster O, Thomas JM, Hamzah J, et al. Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release. 2012;161(3):804–812. doi:10.1016/j.jconrel.2012.05.035.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Cook KE, Damschroder MM, et al. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol. 2006;177(2):1129–1138. doi:10.4049/jimmunol.177.2.1129.
   PubMed Web of Science ®Google Scholar
• Igawa T, Haraya K, Hattori K. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Immunol Rev. 2016;270(1):132–151. doi:10.1111/imr.12392.
   PubMed Web of Science ®Google Scholar
• Choi DK, Bae J, Shin SM, et al. A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells. MAbs. 2014;6(6):1402–1414. doi:10.4161/mabs.36389.
   PubMed Web of Science ®Google Scholar
• Kim J-S, Choi D-K, Shin J-Y, et al. Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape. J Control Release. 2016;235:165–175. doi:10.1016/j.jconrel.2016.05.066.
   PubMed Web of Science ®Google Scholar
• Sedykh SE, Prinz VV, Buneva VN, et al. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195–208. doi:10.2147/DDDT.S151282.
   PubMed Web of Science ®Google Scholar
• Wozniak-Knopp G. Bispecific antibodies. In: Rüker F, Wozniak-Knopp G., eds. Introduction to Antibody Engineering. Cham: Springer; 2021:161–187.
   Google Scholar
• Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol. 2016;40:24–35. doi:10.1016/j.coi.2016.02.006.
   PubMed Web of Science ®Google Scholar
• Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin. 2010;31(9):1198–1207. doi:10.1038/aps.2010.120.
   PubMed Web of Science ®Google Scholar
• Jarasch A, Koll H, Regula JT, et al. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci. 2015;104(6) :1885–1898. doi:10.1002/jps.24430.
   PubMed Web of Science ®Google Scholar
• de Jong RN, Beurskens FJ, Verploegen S, et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 2016;14(1):e1002344. doi:10.1371/journal.pbio.1002344.
   PubMed Web of Science ®Google Scholar
• Chiu ML, Gilliland GL. Engineering antibody therapeutics. Curr Opin Struct Biol. 2016;38:163–173. doi:10.1016/j.sbi.2016.07.012.
   PubMed Web of Science ®Google Scholar
• Smith SA, Crowe JE.Jr. Use of human hybridoma technology to isolate human monoclonal antibodies. Antibodies Infect Dis. 2015;141–156.
   Google Scholar
• Tiller T. Single B cell antibody technologies. N Biotechnol. 2011;28(5) :453–457. doi:10.1016/j.nbt.2011.03.014.
   PubMed Web of Science ®Google Scholar
• Yang X, Xu W, Dukleska S, et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs. 2013;5(5):787–794. doi:10.4161/mabs.25269.
   PubMed Web of Science ®Google Scholar
• Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. MAbs. 2011;3(3):253–263. doi:10.4161/mabs.3.3.15608.
   PubMed Web of Science ®Google Scholar
• Kornmann H, Hock B. Engineering therapeutic antibodies for development. In: Rüker F, Wozniak-Knopp G., eds. Introduction to Antibody Engineering. Cham: Springer; 2021: 319–341.
   Google Scholar
• Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs. 2011;3(2):107–110. doi:10.4161/mabs.3.2.14785.
   PubMed Web of Science ®Google Scholar
• Hillman Y, Lustiger D, Wine Y. Antibody-based nanotechnology. Nanotechnology. 2019;30(28) :282001. doi:10.1088/1361-6528/ab12f4.
   PubMed Web of Science ®Google Scholar
• Food F. and D. Adminstration. Coronavirus (COVID-19) Update: fda Revokes Emergency Use Authorization for Chembio Antibody Test. News Release, 2020.
   Google Scholar
• Manish M, Verma S, Kandari D, et al. Anthrax prevention through vaccine and post-exposure therapy. Expert Opin Biol Ther. 2020;20(12):1405–1425. doi:10.1080/14712598.2020.1801626.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies . Expert Opin Biol Ther. 2016;16(12):1455–1468. doi:10.1080/14712598.2016.1230195.
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discovery. 2021.
   Web of Science ®Google Scholar
• Chibber P, Haq SA, Ahmed I, et al. Advances in the possible treatment of COVID-19: a review. Eur J PharmacolPharmacol. 2020;883:173372. doi:10.1016/j.ejphar.2020.173372.
   PubMed Web of Science ®Google Scholar